ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Mar 10, 2021

Keywords

ClinConnect Summary

The ANCA II trial is studying how anal cancer affects the quality of life and everyday functioning of patients. Anal cancer is a rare but increasing condition, and while many patients respond well to treatment like chemotherapy and radiotherapy, some may experience side effects or have ongoing health issues after their treatment. This study aims to understand these issues better by looking at patients from the time they are diagnosed, assessing any treatment-related problems early on, and tracking their health over the long term.

To participate in this trial, individuals must be over 18 years old and have been diagnosed with anal squamous carcinoma within the last two months. Unfortunately, those who cannot provide informed consent will not be eligible. Participants can expect to be closely monitored throughout their treatment journey, helping researchers gain valuable insights into the effects of anal cancer and its treatment on patients' lives. This information could lead to improved care and support for future patients facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • Anal squamous carcinoma diagnosed within the last 2 months
• Exclusion Criteria:
• • -No informed consent